Novo Nordisk’s Rally Faces a Critical Test as Medicare Catalyst and Pricing Headwinds Converge
Published on 06/25/2026 at 06:12 | Redaktion boerse-global.de
The Danish drugmaker’s shares have surged nearly 11% over the past seven days, closing at €41.81 on Wednesday as a flurry of catalysts — from a historic Medicare expansion to a blockbuster pill launch — propelled the stock back above its 200-day moving average. Yet beneath the surface, the same forces driving the rally also contain the seeds of a potential reversal.
Medicare Opens the Door, but at a Price
On July 1, the US Centers for Medicare & Medicaid Services will activate the GLP-1 Bridge Program, granting millions of seniors access to weight-loss drugs like Wegovy for the first time in over two decades. Patients will pay a monthly copay of $50, while the government has capped manufacturer reimbursement at $245 per monthly supply. The program runs through the end of 2027 and covers all 50 states and US territories.
For Novo Nordisk and rival Eli Lilly, the opportunity is enormous — up to 20 million newly eligible beneficiaries could enter the market. But the economics are far from straightforward. The fixed price cap limits revenue per patient, meaning Novo must rely on volume growth to offset the squeeze. The company’s own 2026 guidance already projects an adjusted sales decline of 5% to 13%, and first-quarter US revenues fell 11% year-on-year on an adjusted basis, weighed down by lower net prices.
Steady Buyback Provides a Floor
Since February, Novo has been methodically repurchasing its own shares under a programme worth up to DKK 15 billion over 12 months. As of June 19, the company had bought roughly 21 million B-shares at an average price of DKK 266, for a total outlay of about DKK 5.6 billion. The weekly cadence is consistent: during the five trading days from June 15 to 19, Novo snapped up between 190,000 and 225,000 shares each day. This steady demand has helped cushion downside moves.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Pill Launch Defies Expectations
The oral version of Wegovy has emerged as one of the strongest pharmaceutical launches in recent US history. More than three million prescriptions have been written in just over five months — the first million took 12 weeks, the second only ten more. Crucially, over 80% of those prescriptions went to patients who had never taken a GLP-1 drug before, confirming that the pill is expanding the addressable market rather than cannibalising the injectable. The product has already secured approval in the US, UAE, and UK, with additional markets expected in the second half of 2026. European regulators are also reviewing the drug.
To capitalise on the new demand, Novo is investing heavily in production capacity. CEO Lars Fruergaard Jørgensen — who took the helm last year — has announced the elimination of 9,000 positions, aiming to generate annual savings of roughly DKK 8 billion by the end of 2026. The restructuring carries its own operational risks, particularly if research timelines slip.
Competitive Headwinds Remain Formidable
Eli Lilly still commands around 60% of the US obesity market, leaving Novo Nordisk with a 39% share. Lilly’s Zepbound delivered 25.5% weight loss in a head-to-head trial, compared to 23% for Novo’s internal candidate CagriSema over 84 weeks — a gap that has analysts questioning the latter’s competitive edge. Meanwhile, Pfizer and other players are rushing to enter the field.
Deutsche Bank sees limited upside for Novo’s cardiovascular candidate Ziltivekimab, and a patent cliff looms in 2031, with roughly DKK 30 billion in revenue at risk. The next-generation pipeline does offer some hope: Zenagamtide, an oral GLP-1 receptor agonist, posted nearly 15% weight loss in Phase 2 and is slated to enter Phase 3 in the second half of 2026.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
The Verdict Awaits August 5
The stock has recouped more than 38% from its March low of €30.25, yet it still trades about 32% below the 52-week high of €61.20. With the relative strength index hovering near 70, the short-term rally looks technically extended.
The next true litmus test arrives on August 5, when Novo Nordisk reports second-quarter results. Two numbers will determine whether the optimism is justified: the realised net price per Wegovy prescription in the US, and the initial prescription volumes generated by the Medicare programme. If volume gains fail to compensate for price erosion — or if the Bridge Program fails to deliver a meaningful uptick in scripts — the recent advance could quickly unwind. For now, the market is betting that the balance tips toward growth. The data will tell.
Ad
Novo Nordisk Stock: New Analysis - 25 June
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
